ViroCell Biologics Secures Funding for Growth in Gene Therapy
ViroCell Biologics, a prominent organization headquartered in both London, UK, and New York City, USA, has successfully raised an undisclosed amount of funding through a convertible note. This latest funding round was spearheaded by First Light Asset Management LLC, who joined forces with existing investors including Sartorius Stedim Biotech S.A. The financial infusion aims to accelerate the company’s growth trajectory as it capitalizes on its increasing commercial success within the specialized services of viral vector design and manufacturing. This investment reflects a growing confidence in the vital role that cell and gene therapy advancements play in the biopharmaceutical landscape.
Under the leadership of CEO John W.
Hadden II, ViroCell Biologics operates as a dynamic and innovation-driven Contract Development and Manufacturing Organization (CDMO) that specializes exclusively in the intricate processes of designing, derisking, and Good Manufacturing Practice (GMP) production of viral vectors intended for clinical trials. The dedicated team at ViroCell harnesses their extensive experience to assist clients in mitigating risks and expediting the development and clinical testing of novel cell and gene therapies. Their commitment lies in establishing themselves as the preferred partner for both corporate and academic trailblazers who are at the forefront of breakthroughs in this field.
Initially focusing on the production of lentivirus and gamma-retrovirus vectors, ViroCell Biologics provides an effective and scalable platform that allows clients to initiate clinical trials more efficiently. By doing so, they deliver significant value by not only minimizing costs but also reducing the time and regulatory risks commonly associated with such advanced therapeutics. As the landscape of biopharmaceutical development rapidly evolves, ViroCell’s contributions are essential in enabling the swift transition of innovative therapies from concept to clinical application, ultimately benefiting patients worldwide in their quest for cutting-edge medical solutions.
They've invested in ViroCell Biologics
Get to know these Healthtech investors
Click here for a full list of 6,908+ startup investors in the UK